Figure e-1: Patient disposition. Percentages are based on the number of patients randomized in each group.



Screening was performed up to 6 weeks before randomization. After completion (or premature discontinuation) of the 24-week Treatment phase, patients entered the 24-week follow-up, which assessed patient safety and B-cell repletion. Thereafter (Week 48 onwards), individual patients whose CD19+ B-lymphocyte counts remained below the LLN and who did not start a DMT, entered the IFU period. In the IFU, repletion of CD19+ B-lymphocyte counts was monitored until either (i) the B-cell counts returned to LLN or the individual's baseline (if <LLN); (ii) the patient started a DMT; or (iii) beyond Week 120, when circulating levels of immunoglobulin G were ≥LLN or back to baseline levels (if <LLN). The last patient in this phase completed at Week 132.

[a]One patient in each group excluded from the mITT population due to not having post-baseline MRI; bone patient was excluded from the safety population; Percentages are based on the number of patients randomized in each group. CD, conditioning dose; DMT, disease-modifying therapy; IFU, individualized follow-up; mITT, modified intent-to-treat; LLN, lower limit of normal; MRI, magnetic resonance imaging; PBO, placebo; q4w, every 4 weeks; q12w, every 12 weeks.

Figure e-2: Rate ratio (95% CI) versus placebo of cumulative number of new gadolinium-enhancing lesions at week 12: E_{max} model excluding the week 4 scan (mITT population)



Figure e-3: Mean (95% CI) cumulative number of T2 lesions by dose group and visit (see Table 2). (All evaluable scans data set)



CI, confidence interval; q4w, every 4 weeks; q12w every 12 weeks

Figure e-4: Post hoc analysis of predicted new GdE T1 lesions as a function of weighted mean CD19 Bcell count (mean; 95% CI)



CI, confidence interval; GdE, gadolinium enhancing

Figure e-5: Injection-related reactions with or without conditioning dose



Treatment Arms: Treatment schedule

	W0	W1	W4	W8	W12	W16	W20	No of subjects	Randomization ratio
PBO	PBO	PBO	PBO	PBO	3 mg	PBO	PBO	56	4
Ofa 3 mg q12w	PBO	3 mg	PBO	PBO	3 mg	PBO	PBO	28	2
Ofa 30 mg q12w	PBO	30 mg	PBO	PBO	30 mg	PBO	PBO	14	1
Ofa 30 mg q12w + Conditioning dose	3 mg	30 mg	PBO	PBO	30 mg	PBO	PBO	14	1
Ofa 60 mg q12w	PBO	60 mg	PBO	PBO	60 mg	PBO	PBO	14	1
Ofa 60 mg q12w + Conditioning dose	3 mg	60 mg	PBO	PBO	60 mg	PBO	PBO	14	1
Ofa 60 mg q4w	PBO	60 mg	60 mg	60 mg	60 mg	60 mg	60 mg	28	2
Ofa 60 mg q 4w + Conditioning dose	3mg	60 mg	60 mg	60 mg	60 mg	60 mg	60 mg	28	2

Patients randomized to the placebo group received 3 mg ofatumumab at week 12

IRR, injection-related reaction; Ofa, ofatumumab; PBO, placebo; q, every; w, week

Figure e-6: Pharmacokinetics